Please rotate your device

GET PROPEL

Stay Informed

    Stay informed

    Sign up for the PROPEL mailing list

    Provide some basic information and we’ll send you relevant content and event reminders.




    • ENT/Rhinologist
    • Other

    *ALL FIELDS REQUIRED

    By providing the above information, you agree to allow Intersect ENT to provide you with information relating to Intersect ENT’s products. The information you submit will be governed by our Privacy Policy.

      GET PROPEL

      SIGN UP TO GET PROPEL

      Empower your practice with PROPEL. Provide some basic information to connect to a representative.




      • ENT/Rhinologist
      • Other

      *ALL FIELDS REQUIRED

      By providing the above information, you agree to allow Intersect ENT to provide you with information relating to Intersect ENT’s products. The information you submit will be governed by our Privacy Policy.

      You are leaving the HCP website

      You are being directed to a third-party website. Please note that this third-party website is not controlled by PROPELOpens.com.

      Thank you for visiting our site.

      Continue

      Patients with chronic rhinosinusitis (CRS) may benefit from postoperative care that reduces inflammation, in order to achieve improved sinus surgery outcomes

      CRS is an inflammatory disease with often chronic and debilitating
      sinonasal symptoms such as1:

      • Congestion

      • Nasal discharge

      • Facial pain or pressure

      • Loss of smell

      Consider the impact. CRS attacks patients from within, causing substantial damage. Patients with CRS report greater bodily pain and impaired social functioning than do those with angina, congestive heart failure, back pain, and chronic obstructive pulmonary disease.2

      Ultimately, CRS exacts a tremendous economic impact that burdens healthcare systems and patients3

      Direct costs related to CRS:
      $10-$13 billion per year in the USA
      are primarily driven by outpatient doctor visits, prescription medical therapy, and sinus surgery

      Indirect costs related to CRS:
      >$20 billion per year in the USA are primarily driven by lost work capabilities

      Challenges may hold your patients from
      realizing optimal sinus surgery outcomes

      Although some patients may achieve symptom control by medical management, others may benefit from endoscopic sinus surgery (ESS).1,4 However, despite optimal surgical technique, postoperative challenges can limit sinus surgery outcomes. Common challenges include5,6:

      • Scarring or stenosis of surgical opening

      • Recurrent inflammation and polyposis

      • Inadequate delivery of topical therapy

      MAY PREVENT YOUR PATIENTS FROM ACHIEVING OPTIMAL SINUS SURGERY OUTCOMES11,12

      Each sinus has unique challenges during sinus surgery

      • FRONTAL

      • Restenosis is a common challenge, partly due to the anatomically narrow boundaries of the frontal sinus, leading to limited sinusotomy size7
      38

      reduction in
      FSO diameter

      Restenosis is observed following frontal sinus surgery independent of polyps. The average diameter of the frontal sinus ostia (FSO) decreased by 38% (3.5 mm vs 5.6 mm) after 13 months, in patients who underwent traditional ESS8

      • ETHMOID

      • A common complication is middle turbinate lateralization (MTL), which may be associated with an increased risk of revision surgery9
      25

      frequency
      of MTL

      MTL may occur in as many as 25% of patients who had ESS at ≥6 months follow-up9

      more likely to need
      revision surgery

      21% of patients with MTL required revision surgery vs 9% in patients without MTL9

      • MAXILLARY

      • The causes of sinus surgery failure can be attributed to 3 main reasons. Overall, nearly 1 in 5 patients will require revision surgery10

      frequency
      of MTL

      In a retrospective study conducted over a 5-year period, the top 3 causes for maxillary ESS failure were10:

      1. obstructed natural ostia
      2. disease in the anterior ethmoid or frontal sinus
      3. resistant organisms
      Up to
      18

      more likely to need
      revision surgery

      It is estimated that between 2% and 18% of maxillary cases require revision surgery10

      Overall, postoperative inflammation related to surgery and the underlying disease is hard to predict and can hinder the benefits of surgery. So, safe and effective postoperative care options are needed that effectively deliver corticosteroids to the sinus and minimize reliance on patient compliance

      Reducing postoperative inflammation and scarring is essential to help improve long-term patient outcomes and reduce the need for additional interventions11,12

      POSTOPERATIVE CARE DICTATES LONG-TERM OUTCOMES: improvements in quality of life after ESS at 6 months are indicative of results seen at 1.6 years.13

      Elevate your postoperative care regimen beyond traditional options

      In order to maintain the benefits achieved with surgery, postoperative care regimens are needed that ensure that newly opened sinuses remain open and inflammation is controlled from both the underlying disease and the procedure.4 Common postoperative regimens include4,14:

      • Topical steroid sprays
      • Oral steroids
      • Mechanical spacers ± steroids

      Although these regimens have an established role in postoperative care, they do not provide an optimal solution.

      • Topical steroid sprays15,16

      • Poor penetration into the sinus
      • ~60% of active drug in a metered dose of nasal steroid spray is removed by mucociliary clearance within 15 minutes
      • Poor patient compliance
      • Only 40% patients use intranasal corticosteroids as directed

      • Oral steroids17,18

      • Effective in addressing inflammation but carry systemic risks, such as
      • Hyperglycemia
      • Infections
      • Bone loss
      • Adrenal suppression
      • Ophthalmic complication
      • Gastrointestinal symptoms
      • Psychiatric symptoms

      • Mechanical spacers ± steroids14

      • Obstruction impairs drainage
      • Notable variability in steroid dose
      • Unknown release duration of steroid
      • Painful removal
      • Absence of efficacy/safety data from clinical trials

      Historically, there has been an unmet need for postoperative care options proven in randomized controlled trials to significantly improve sinus surgery outcomes

      GET PROPEL

      Stay Informed

      This site is intended for healthcare professionals in the United States

      Instructions for Use:

      PROPEL PROPEL MINI PROPEL MINI WITH SDS PROPEL Contour

      Instructions for Use (EU):

      PROPEL PROPEL MINI
      Stay Informed

      References

      1. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015; 152(2 suppl):S1-S39.
      2. Gliklich RE, Metson R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol Head Neck Surg. 1995;113(1):104-109.
      3. Rudmik L. Economics of Chronic Rhinosinusitis. Curr Allergy Asthma Rep. 2017;17(4):20.
      4. Sedaghat AR. Chronic Rhinosinusitis. Am Fam Physician. 2017;96(8):500-506.
      5. Ramadan HH. Surgical causes of failure in endoscopic sinus surgery. Laryngoscope. 1999;109(1):27-29
      6. Otto KJ, DelGaudio JM. Operative findings in the frontal recess at time of revision surgery. Am J Otolaryngol. 2010;31(3):175-180.
      7. Luong A, Ow RA, Singh A, et al. Safety and effectiveness of a bioabsorbable steroid-releasing implant for the paranasal sinus ostia: a randomized clinical trial [published online ahead of print]. JAMA Otolaryngol Head Neck Surg. 2017. doi:10.1001/jamaoto.2017.1859.
      8. Hosemann W, Kühnel T, Held P, et al. Endonasal frontal sinusotomy in surgical management of chronic sinusitis: a critical evaluation. Am J Rhinol. 1997;11(1):1-9.
      9. Bassiouni A, Chen PG, Naidoo Y, Wormald PJ. Clinical significance of middle turbinate lateralization after endoscopic sinus surgery. Laryngoscope. 2015;125(1):36-41.
      10. Richtsmeier WJ. Top 10 reasons for endoscopic maxillary sinus surgery failure. Laryngoscope. 2001;111(11 Pt 1):1952-1956.
      11. Kennedy DW, Wright ED, Goldberg AN. Objective and subjective outcomes in surgery for chronic sinusitis. Laryngoscope. 2000;110(3 Pt 3):29-31.
      12. Kennedy DW. The PROPEL™ steroid-releasing bioabsorbable implant to improve outcomes of sinus surgery. Expert Rev Respir Med. 2012;6(5):493-498.
      13. Soler ZM, Smith TL. Quality-of-life outcomes after endoscopic sinus surgery: how long is long enough? Otolaryngol Head Neck Surg. 2010;143(5):621-625.
      14. Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
      15. Shah SA, Berger RL, McDermott J, et al. Regional deposition of mometasone furoate nasal spray suspension in humans. Allergy Asthma Proc. 2015;36(1):48-57.
      16. Nabi S, Rotenberg BW, Vukin I, et al. Nasal spray adherence after sinus surgery: problems and predictors. J Otolaryngol Head Neck Surg. 2012;41(suppl 1): S49-S55.
      17. Cope D, Bova R. Steroids in otolaryngology. Laryngoscope. 2008;118(9):1556-1560.
      18. Shen J, Welch K, Kern R. Mometasone furoate sinus implant - a new targeted approach to treating recurrent nasal polyp disease. Expert Rev Clin Pharmacol. 2018;11(12):1163-1170.

      The PROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

      Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries.

      The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/foreign patents, found at intersectent.com/patents.

      ©2021 Intersect ENT, Inc. All rights reserved. MPM-11549 Rev 4.0